Skip to content
Beacon

LABUDirexion Daily S&P Biotech Bull 3X Shares

Take a bet#59 of 761 for Take a bet

Seeks daily investment results of 300% of the daily performance of the S&P Biotechnology Select Industry Index.

Direxion Funds · Since 2015 (10 years)

Annual Cost

0.96%

#4569 out of 5,332 ETFs

Fund Size

$561M

#1346 out of 5,332 ETFs

Dividend Yield

0.74%

Track Record

10 years

#1309 out of 5,332 ETFs

Performance

1 Year

+189.3%

3 Years

+17.8%

5 Years

-36.1%

What's inside

Asset class
Strategy
leveraged
Cap
multi cap

Asset allocation

Stocks
77.1%
Cash
22.9%

Sector breakdown

Healthcare
99.8%
Financial Services
0.2%

Top holdings

Apellis Pharmaceuticals IncAPLS1.3%
Alkermes PLCALKS1.0%
Madrigal Pharmaceuticals IncMDGL1.0%
TG Therapeutics IncTGTX0.9%

Risk profile

Volatility (1Y)

77.5%

High

Max drawdown

-99.0%

Worst peak-to-trough loss

Sharpe (3Y)

0.56

Decent risk-adjusted returns

Sortino (3Y)

0.82

Moderate downside risk

Similar ETFs

Our take

Structural notes on how this fund behaves. Read our guide on the 6 warning signs.

Leveraged
Warning

Leveraged ETF — not a long-term hold

This fund uses leverage to amplify daily returns (e.g. 2x or 3x of an index). Daily rebalancing creates volatility decay — over weeks and months, the fund's return drifts from the stated multiple. In trending markets with low realised volatility, leveraged index ETFs can outperform their nominal multiple; in sideways or volatile markets they bleed. Designed for short-term tactical use, not buy-and-hold.

Source: Cheng & Madhavan, 'The Dynamics of Leveraged and Inverse ETFs' (2009)

Why we flagged this: strategy=leveraged + leveraged_name_or_strategy

Educational analysis of structural product characteristics. Not investment advice. Always read the fund prospectus and consult a qualified advisor before investing. More

Data updated on 2026-05-05